Souhaitez-vous accéder aux communiqués récents ?

Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Market Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides" has been added to ...

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute...

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around...

Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...

Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Peanut Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ...

Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pollen Allergy was valued...

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with...

Intrommune welcomes an independent editorial that was recently published in Annals of Allergy, Asthma & Immunology.

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project led by Dr. Sheila Singh and her team at McMaster University. The project...

Lumanity announces a new partnership to accelerate the lab to bedside journey for cancer patients with the Parker Institute for Cancer Immunotherapy.